This article is more than 5 years old. Information may no longer be current.
Allergan reports 23% rise in first-quarter total product net sales
Click Here to Manage Email Alerts
IRVINE, Calif. — Allergan reported $1.06 billion in total product net sales for the first quarter, up 23%, or 18.5% at constant currency, compared with total net product sales in the first quarter of 2007, the company announced in a press release.
For the first quarter, total specialty pharmaceutical net sales rose 23%, or 18.6% at constant currency, while total medical device net sales rose 23.1%, or 18% at constant currency, compared with net sales during the first quarter of 2007.
Specifically, Allergan reported $492.2 million in total eye care pharmaceutical sales, a 22.1% increase over $403 million in the first quarter of 2007. Alphagan P (brimonidine tartrate 0.15%), Alphagan (brimonidine tartrate) and Combigan (0.2% brimonidine tartrate, 0.5% timolol maleate) sales totaled $99.5 million, up 28.4% compared with $77.5 million for the same period last year, according to the release.
In addition, total Lumigan (bimatoprost) product sales rose 20.7% to $107.5 million, and Restasis (cyclosporine ophthalmic emulsion) sales rose 27.8% to $100.2 million during the quarter.
For the second quarter, Allergan expects to post total net product sales between $1.13 billion and $1.16 billion.
The company's board of directors also declared a first quarter dividend of $0.05 per share, which is payable on June 13 to stockholders on record as of May 23, the release said.